Cargando…

Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration

BACKGROUND: Sasanlimab is a monoclonal antibody that binds to the programmed cell death receptor 1 (PD-1). Anti-PD-1 monoclonal antibodies have improved patient clinical outcomes; however, not all treated patients derive clinical benefit. Further insights on potential biomarkers beyond PD-L1 express...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu-Lieskovan, Siwen, Braiteh, Fadi, Grilley-Olson, Juneko E., Wang, Xiao, Forgie, Alison, Bonato, Vinicius, Jacobs, Ira A., Chou, Jeffrey, Johnson, Melissa L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613140/ https://www.ncbi.nlm.nih.gov/pubmed/34694529 http://dx.doi.org/10.1007/s11523-021-00833-2

Ejemplares similares

A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma
por: Cho, B.C., et al.
Publicado: (2023)

What does PD-L1 positive or negative mean?
por: Ribas, Antoni, et al.
Publicado: (2016)

Improved Tumor Purity Metrics in Next-generation Sequencing for Clinical Practice: The Integrated Interpretation of Neoplastic Cellularity and Sequencing Results (IINCaSe) Approach
por: Patel, Nirali M., et al.
Publicado: (2019)

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis
por: Allen, Clint T., et al.
Publicado: (2019)

MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction
por: Irving, Bryan A, et al.
Publicado: (2013)

High response rate to PD-1 blockade in desmoplastic melanomas
por: Eroglu, Zeynep, et al.
Publicado: (2018)

Molecular determinants of response to PD-L1 blockade across tumor types
por: Banchereau, Romain, et al.
Publicado: (2021)

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure
por: Shin, Daniel, et al.
Publicado: (2015)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
por: Davda, Jasmine, et al.
Publicado: (2019)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

Blockade of Tumor-Expressed PD-1 promotes lung cancer growth
por: Du, Shisuo, et al.
Publicado: (2018)

Clonal replacement of tumor-specific T cells following PD-1 blockade
por: Yost, Kathryn E., et al.
Publicado: (2019)

Non-synergy of PD-1 blockade with T-cell therapy in solid tumors
por: Davies, John S, et al.
Publicado: (2022)

Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment
por: Koyama, Shohei, et al.
Publicado: (2018)

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
por: Šmahel, Michal
Publicado: (2017)

PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness
por: Chen, Xiangyu, et al.
Publicado: (2023)

PD-L1 blockade enhances anti-tumor efficacy of NK cells
por: Oyer, Jeremiah L., et al.
Publicado: (2018)

PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
por: Zahm, Christopher D., et al.
Publicado: (2021)

Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors
por: Benguigui, Madeleine, et al.
Publicado: (2022)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
por: Wang, Yiting, et al.
Publicado: (2018)

Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
por: Yue, Chunyan, et al.
Publicado: (2018)

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
por: Tomlins, Scott A., et al.
Publicado: (2023)

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
por: Zheng, Ming
Publicado: (2022)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
por: Zhao, Mingxia, et al.
Publicado: (2019)

Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy
por: Kumar, Alok, et al.
Publicado: (2020)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
por: Hamid, Omid, et al.
Publicado: (2022)

Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade
por: Maekawa, Naoya, et al.
Publicado: (2014)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer
por: Chera, Bhishamjit S., et al.
Publicado: (2020)

Dynamic monitoring of serum specific tumor markers predicts the response to PD-1 blockade and prognosis of patients with malignant tumors
por: Dong, Qian, et al.
Publicado: (2021)

Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
por: Zhang, Ze, et al.
Publicado: (2021)

Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
por: Minnar, Christine M, et al.
Publicado: (2022)

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
por: Siu, Lillian, et al.
Publicado: (2020)

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
por: Wang, Ziming, et al.
Publicado: (2018)

In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
por: Bartee, Eric, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aeee37hvu1nohk184pl8f4r082